Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis (Journal for ImmunoTherapy of Cancer (2018) 6 (103) DOI: 10.1186/s40425-018-0412-0)

Following publication of the original article [1], the authors reported an error in their listed affiliations. This error was introduced during typesetting and the publisher apologizes to readers and the authors for the inconvenience. In this Correction the authors are listed with their correct affiliations below. Daniel H Johnson¹, Chrystia M Zobniw², Van A Trinh², Junsheng Ma³, Roland L Bassett Jr³, Noha Abdel-Wahab^4,5, Jaime Anderson², Jennifer E Davis⁶, Jocelyn Joseph², Marc Uemura¹, Ali Noman⁷, Hamzah Abu-Sbeih⁷, Cassian Yee¹, Rodabe Amaria¹, Sapna Patel¹, Hussein Tawbi¹, Isabella C Glitza¹, Michael A Davies¹, Michael K Wong¹, Scott Woodman¹, Wen-Jen Hwu¹, Patrick Hwu¹, Yinghong Wang⁷ and Adi Diab¹. ¹Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ²Division of Pharmacy, Clinical Section, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ³Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁴Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁵Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt. ⁶Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁷Department of Gastroenterology, Hepatology, and Nutrition, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.